Key result
ACE inhibitors reduced myocardial infarction risk versus other antihypertensives (OR 0.78; 95% CI 0.63-0.97), with the greatest reduction in carriers of the ACE-4656-G allele.
Why the study?
Does genetic variation in the renin-angiotensin system modify the risk of myocardial infarction related to ACE inhibitors and AT II antagonists in users of antihypertensive drugs?
Case-Control (n=4,243)
Does genetic variation in the renin-angiotensin system modify the risk of myocardial infarction related to ACE inhibitors and AT II antagonists in users of antihypertensive drugs?
Effect estimate: OR 0.78 (95% CI 0.63-0.97)
Genetic variations in the renin-angiotensin system, specifically the ACE-G4656C polymorphism, modify the effectiveness of ACE inhibitors in preventing myocardial infarction.
No takes yet. Share an insight, caveat, or question.
ACE inhibitors may confer greater MI protection in ACE-4656-G carriers; hypothesis-generating for pharmacogenetic tailoring pending prospective validation.
Zee et al. (2010) conducted a case-control in Myocardial infarction in users of antihypertensive drugs (n=4,243). ACE inhibitors vs. Other antihypertensives was evaluated on Risk of myocardial infarction (OR 0.78, 95% CI 0.63-0.97). ACE inhibitors reduced myocardial infarction risk versus other antihypertensives (OR 0.78; 95% CI 0.63-0.97), with the greatest reduction in carriers of the ACE-4656-G allele.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: